Timing of radiotherapy after radical prostatectomy (RADICALS-RT): a randomised, controlled phase 3 trial

Published on Sep 28, 2020in The Lancet60.392
· DOI :10.1016/S0140-6736(20)31553-1
Chris Parker83
Estimated H-index: 83
Noel W. Clarke71
Estimated H-index: 71
(University of Salford)
+ 45 AuthorsMatthew R. Sydes70
Estimated H-index: 70
Summary Background The optimal timing of radiotherapy after radical prostatectomy for prostate cancer is uncertain. We aimed to compare the efficacy and safety of adjuvant radiotherapy versus an observation policy with salvage radiotherapy for prostate-specific antigen (PSA) biochemical progression. Methods We did a randomised controlled trial enrolling patients with at least one risk factor (pathological T-stage 3 or 4, Gleason score of 7–10, positive margins, or preoperative PSA ≥10 ng/mL) for biochemical progression after radical prostatectomy (RADICALS-RT). The study took place in trial-accredited centres in Canada, Denmark, Ireland, and the UK. Patients were randomly assigned in a 1:1 ratio to adjuvant radiotherapy or an observation policy with salvage radiotherapy for PSA biochemical progression (PSA ≥0·1 ng/mL or three consecutive rises). Masking was not deemed feasible. Stratification factors were Gleason score, margin status, planned radiotherapy schedule (52·5 Gy in 20 fractions or 66 Gy in 33 fractions), and centre. The primary outcome measure was freedom from distant metastases, designed with 80% power to detect an improvement from 90% with salvage radiotherapy (control) to 95% at 10 years with adjuvant radiotherapy. We report on biochemical progression-free survival, freedom from non-protocol hormone therapy, safety, and patient-reported outcomes. Standard survival analysis methods were used. A hazard ratio (HR) of less than 1 favoured adjuvant radiotherapy. This study is registered with ClinicalTrials.gov, NCT00541047. Findings Between Nov 22, 2007, and Dec 30, 2016, 1396 patients were randomly assigned, 699 (50%) to salvage radiotherapy and 697 (50%) to adjuvant radiotherapy. Allocated groups were balanced with a median age of 65 years (IQR 60–68). Median follow-up was 4·9 years (IQR 3·0–6·1). 649 (93%) of 697 participants in the adjuvant radiotherapy group reported radiotherapy within 6 months; 228 (33%) of 699 in the salvage radiotherapy group reported radiotherapy within 8 years after randomisation. With 169 events, 5-year biochemical progression-free survival was 85% for those in the adjuvant radiotherapy group and 88% for those in the salvage radiotherapy group (HR 1·10, 95% CI 0·81–1·49; p=0·56). Freedom from non-protocol hormone therapy at 5 years was 93% for those in the adjuvant radiotherapy group versus 92% for those in the salvage radiotherapy group (HR 0·88, 95% CI 0·58–1·33; p=0·53). Self-reported urinary incontinence was worse at 1 year for those in the adjuvant radiotherapy group (mean score 4·8 vs 4·0; p=0·0023). Grade 3–4 urethral stricture within 2 years was reported in 6% of individuals in the adjuvant radiotherapy group versus 4% in the salvage radiotherapy group (p=0·020). Interpretation These initial results do not support routine administration of adjuvant radiotherapy after radical prostatectomy. Adjuvant radiotherapy increases the risk of urinary morbidity. An observation policy with salvage radiotherapy for PSA biochemical progression should be the current standard after radical prostatectomy. Funding Cancer Research UK, MRC Clinical Trials Unit, and Canadian Cancer Society.
📖 Papers frequently viewed together
1,187 Citations
201260.39The Lancet
19 Authors (Michel Bolla, ..., Laurence Collette)
555 Citations
23 Authors (Andrew Kneebone, ..., Maria Pearse)
28 Citations
#1Claire L Vale (UCL: University College London)H-Index: 25
#2David Fisher (UCL: University College London)H-Index: 23
Last. Jayne F. Tierney (UCL: University College London)H-Index: 55
view all 18 authors...
Summary Background It is unclear whether adjuvant or early salvage radiotherapy following radical prostatectomy is more appropriate for men who present with localised or locally advanced prostate cancer. We aimed to prospectively plan a systematic review of randomised controlled trials (RCTs) comparing these radiotherapy approaches. Methods We used a prospective framework for adaptive meta-analysis (FAME), starting the review process while eligible trials were ongoing. RCTs were eligible if they...
34 CitationsSource
#1Andrew Kneebone (USYD: University of Sydney)H-Index: 29
Last. Maria PearseH-Index: 9
view all 23 authors...
Summary Background Adjuvant radiotherapy has been shown to halve the risk of biochemical progression for patients with high-risk disease after radical prostatectomy. Early salvage radiotherapy could result in similar biochemical control with lower treatment toxicity. We aimed to compare biochemical progression between patients given adjuvant radiotherapy and those given salvage radiotherapy. Methods We did a phase 3, randomised, controlled, non-inferiority trial across 32 oncology centres in Aus...
28 CitationsSource
#1Paul SargosH-Index: 18
#2Sylvie ChabaudH-Index: 26
Last. Pierre RichaudH-Index: 30
view all 18 authors...
Summary Background Adjuvant radiotherapy reduces the risk of biochemical progression in prostate cancer patients after radical prostatectomy. We aimed to compare adjuvant versus early salvage radiotherapy after radical prostatectomy, combined with short-term hormonal therapy, in terms of oncological outcomes and tolerance. Methods GETUG-AFU 17 was a randomised, open-label, multicentre, phase 3 trial done at 46 French hospitals. Men aged at least 18 years who had an Eastern Cooperative Oncology G...
30 CitationsSource
#1Christian Carrie (University of Lyon)H-Index: 49
#2Nicolas MagnéH-Index: 48
Last. Sylvie ChabaudH-Index: 26
view all 22 authors...
Summary Background Radiotherapy is the standard salvage treatment after radical prostatectomy. To date, the role of androgen deprivation therapy has not been formally shown. In this follow-up study, we aimed to update the results of the GETUG-AFU 16 trial, which assessed the efficacy of radiotherapy plus androgen suppression versus radiotherapy alone. Methods GETUG-AFU 16 was an open-label, multicentre, phase 3, randomised, controlled trial that enrolled men (aged ≥18 years) with Eastern Coopera...
40 CitationsSource
#1Greetta Hackman (UH: University of Helsinki)H-Index: 1
#2Kimmo Taari (UH: University of Helsinki)H-Index: 29
Last. Akseli Hemminki (UH: University of Helsinki)H-Index: 76
view all 21 authors...
Abstract Background It remains unclear whether patients with positive surgical margins or extracapsular extension benefit from adjuvant radiotherapy following radical prostatectomy. Objective To compare the effectiveness and tolerability of adjuvant radiotherapy following radical prostatectomy. Design, setting, and participants This was a randomised, open-label, parallel-group trial. A total of 250 patients were enrolled between April 2004 and October 2012 in eight Finnish hospitals, with pT2 wi...
18 CitationsSource
#1Tim P. Morris (UCL: University College London)H-Index: 27
#2Christopher I Jarvis (Lond: University of London)H-Index: 26
Last. Matthew R. Sydes (UCL: University College London)H-Index: 70
view all 6 authors...
Objectives To examine reactions to the proposed improvements to standard Kaplan–Meier plots, the standard way to present time-to-event data, and to understand which (if any) facilitated better depiction of (1) the state of patients over time, and (2) uncertainty over time in the estimates of survival. Design A survey of stakeholders’ opinions on the proposals. Setting A web-based survey, open to international participation, for those with an interest in visualisation of time-to-event data. Parti...
8 CitationsSource
#1Matthew G. Parry (RCS: Royal College of Surgeons of England)H-Index: 8
#2Arunan Sujenthiran (RCS: Royal College of Surgeons of England)H-Index: 9
Last. Jan van der Meulen (Lond: University of London)H-Index: 61
view all 9 authors...
In many countries, specialist cancer services are centralised to improve outcomes. We explored how centralisation affects the radical treatment of high-risk and locally advanced prostate cancer in the English NHS. 79,085 patients diagnosed with high-risk and locally advanced prostate cancer in England (April 2014 to March 2016) were identified in the National Prostate Cancer Audit database. Poisson models were used to estimate risk ratios (RR) for undergoing radical treatment by whether men were...
4 CitationsSource
#1Alan Pollack (UM: University of Miami)H-Index: 83
#2Theodore KarrisonH-Index: 88
Last. H.M. Sandler (Cedars-Sinai Medical Center)H-Index: 14
view all 19 authors...
70 CitationsSource
#1B.S. Chera (UNC: University of North Carolina at Chapel Hill)H-Index: 5
#2Sunil Kumar (UNC: University of North Carolina at Chapel Hill)H-Index: 4
Last. Gaorav P. Gupta (UNC: University of North Carolina at Chapel Hill)H-Index: 24
view all 16 authors...
5 CitationsSource
#1Shearwood McClelland rd (IU: Indiana University)H-Index: 1
#2Kiri A. Sandler (UCLA: University of California, Los Angeles)H-Index: 10
Last. Timur Mitin (OHSU: Oregon Health & Science University)H-Index: 3
view all 5 authors...
Introduction: The management of patients with high-risk features after radical prostatectomy (RP) is controversial. Level 1 evidence demonstrates that adjuvant radiation therapy (RT) improves survival compared to no treatment; however, it may overtreat up to 30% of patients, as randomized clinical trials (RCTs) using salvage RT on observation arms failed to reveal a survival advantage of adjuvant RT. We, therefore, sought to determine the current view of adjuvant vs. salvage RT among North Ameri...
1 CitationsSource
Cited By28
#1Fernando Munoz (AUSL: Academy for Urban School Leadership)H-Index: 11
#2Giuseppe SanguinetiH-Index: 37
Last. A. FaiellaH-Index: 5
view all 0 authors...
Background: Baseline urinary incontinence (UI) strongly modulates UI recovery after adjuvant/salvage radiotherapy (ART/SRT), inducing clinicians to postpone it “as much as possible”, maximizing UI recovery but possibly reducing efficacy. This series aims to analyze the trend of UI recovery and its predictors at radiotherapy start. Methods: A population of 408 patients treated with ART/SRT enrolled in a cohort study (ClinicalTrials.gov #NCT02803086) aimed at developing predictive models of radiat...
#1Derya TilkiH-Index: 57
#2Ming-Hui Chen (UConn: University of Connecticut)H-Index: 91
Last. Anthony V. D'Amico (Brigham and Women's Hospital)H-Index: 93
view all 14 authors...
PURPOSE Adjuvant compared with early salvage radiation therapy (sRT) following radical prostatectomy (RP) has not been shown to reduce progression-free survival in randomized controlled trials. However, these trials might have missed a benefit in men with adverse pathology at RP given that these men were under-represented and immortal time bias might have been present; herein, we investigate this possibility. METHODS We evaluated the impact of adjuvant versus early sRT on all-cause mortality (AC...
#1Ashesh B. Jani (Emory University)H-Index: 35
#2Eduard Schreibmann (Emory University)H-Index: 28
Last. David M. Schuster (Emory University)H-Index: 33
view all 19 authors...
Summary Background Molecular imaging is increasingly used to guide treatment decisions and planning in prostate cancer. We aimed to evaluate the role of 18F-fluciclovine-PET/CT in improving cancer control compared with conventional imaging (bone scan and either CT or MRI) alone for salvage postprostatectomy radiotherapy. Methods In EMPIRE-1, a single-centre, open-label, phase 2/3 randomised controlled trial, patients with prostate cancer with detectable PSA after prostatectomy and negative conve...
#1Michael J. Morris (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 66
#2Jose Mauricio Mota (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 16
Last. Howard I. Scher (Cornell University)H-Index: 62
view all 14 authors...
Abstract Background No standard of care exists for patients with high-risk biochemical recurrence (BCR) after prostatectomy. Objective To evaluate whether addition of docetaxel to androgen deprivation therapy (ADT) improved progression-free survival (PFS) in high-risk BCR patients. Design, setting, and participants TAX3503 was a multicenter phase 3 trial that randomized patients with high-risk BCR to ADT for 18 mo ± docetaxel (75 mg/m2 q3w for ten cycles). Eligibility included prostate-specific ...
#1Shauna R. Campbell (Cleveland Clinic)H-Index: 4
#2M.C. Tom (Baptist Hospital of Miami)H-Index: 1
Last. Rahul D. Tendulkar (Cleveland Clinic)H-Index: 21
view all 13 authors...
BACKGROUND Salvage radiotherapy (SRT) is an established treatment for men with biochemical recurrence following radical prostatectomy (RP). There are several risk factors associated with adverse outcomes; however, the value of postoperative prostate-specific antigen (PSA) kinetics is less clear in the ultrasensitive PSA era. OBJECTIVE To characterize the impact of PSA kinetics on outcomes following SRT and generate nomograms to aid in identifying patients with an increased risk of adverse clinic...
#1Jure Murgic (University of Zagreb)H-Index: 8
#2Blanka Jakšić (University of Zagreb)H-Index: 4
Last. Ana Fröbe (University of Zagreb)H-Index: 5
view all 16 authors...
Background Hypofractionated post-prostatectomy radiotherapy is emerging practice, however with no randomized evidence so far to support it's use. Additionally, patients with persistent PSA after prostatectomy may have aggressive disease and respond less well on standard salvage treatment. Herein we report outcomes for conventionally fractionated (CFR) and hypofractionated radiotherapy (HFR) in patients with persistent postprostatectomy PSA who received salvage radiotherapy to prostate bed. Metho...
#1F. Couñago (UEM: European University of Madrid)
#2Mario Alvarez-Maestro (Hospital Universitario La Paz)H-Index: 10
#1Jayne F. Tierney (UCL: University College London)H-Index: 55
#2David Fisher (UCL: University College London)H-Index: 23
Last. Mahesh K. B. Parmar (UCL: University College London)H-Index: 80
view all 9 authors...
BACKGROUND The vast majority of systematic reviews are planned retrospectively, once most eligible trials have completed and reported, and are based on aggregate data that can be extracted from publications. Prior knowledge of trial results can introduce bias into both review and meta-analysis methods, and the omission of unpublished data can lead to reporting biases. We present a collaborative framework for prospective, adaptive meta-analysis (FAME) of aggregate data to provide results that are...
#1Chris Parker (ICR: Institute of Cancer Research)H-Index: 83
#2Paul SargosH-Index: 18
Last. Claire L Vale (UCL: University College London)H-Index: 25
view all 5 authors...
#1Barry W. Goy (KP: Kaiser Permanente)H-Index: 3
#2In-Lu Amy Liu (KP: Kaiser Permanente)
Abstract null null Background null To assess 12-year outcomes on radical prostatectomy with T3/positive margins, while categorizing patients into risk groups. null null null Methods null From 2004 to 2007, 862 radical prostatectomy patients had T3/positive margins. Management included surveillance (54.8%), salvage radiation therapy (SRT) (36.8%), and primary androgen deprivation therapy (ADT) (8.5%). Freedom from biochemical failure, metastasis-free-survival (MFS), prostate cancer–specific survi...